2197 Stock Overview
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates.
Clover Biopharmaceuticals, Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.71|
|52 Week High||HK$5.78|
|52 Week Low||HK$0.53|
|1 Month Change||7.58%|
|3 Month Change||-39.83%|
|1 Year Change||-84.86%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-94.53%|
Recent News & Updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In GrowthMar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?Nov 29
Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?Aug 31
We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash WiselyApr 28
Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value EstimateFeb 05
|2197||HK Biotechs||HK Market|
Return vs Industry: 2197 underperformed the Hong Kong Biotechs industry which returned -12.7% over the past year.
Return vs Market: 2197 underperformed the Hong Kong Market which returned -8.1% over the past year.
|2197 Average Weekly Movement||12.4%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||14.6%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2197 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: 2197's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
|2007||681||Joshua G. Liang||https://www.cloverbiopharma.com|
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform.
Clover Biopharmaceuticals, Ltd. Fundamentals Summary
|2197 fundamental statistics|
Is 2197 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2197 income statement (TTM)|
|Cost of Revenue||CN¥1.72b|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||-258,830.35%|
How did 2197 perform over the long term?See historical performance and comparison